https://boris-portal.unibe.ch/entities/publication/ee866270-4239-45c4-9b18-25a97d2b31af
Correction: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body...
gip receptorcorrectionimproves
https://pubmed.ncbi.nlm.nih.gov/31451430/
Physiological roles of the GIP receptor in murine brown adipose tissue
The BAT GIPR is linked to the control of metabolic gene expression, fuel utilization, and oxygen consumption. However, the selective loss of the GIPR within...
of thegip receptorphysiologicalroles
https://pmc.ncbi.nlm.nih.gov/articles/PMC12516549/
Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut...
As a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, Tirzepatide (TZP) is a recently...
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1431292/full
Frontiers | Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor...
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are two incretins that bind to their respective receptors and activate...
mechanisms of actiontherapeutic applications
https://vivo.colorado.edu/display/pubid_392211
Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists | CU Experts | CU Boulder
https://events.diabetes.org/p/s/first-in-human-study-demonstrates-gip-receptor-gipr-antagonist-at7687-as-well-tolerated-and-suitable-for-once-weekly-subcutaneous-injection-for-treatment-in-people-living-with-obesity-5399
First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and...
first in human study
https://events.diabetes.org/p/s/results-of-first-phase-3-study-of-retatrutide-a-gip-glp-1-and-glucagon-receptor-agonist-in-patients-with-obesity-triumph-1-5581
Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in...
https://pmc.ncbi.nlm.nih.gov/articles/PMC9438179/
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with...
Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an...
https://events.diabetes.org/p/s/what-does-glucagon-receptor-agonism-add-to-the-effects-of-gip-and-glp-1-receptor-agonism-5584
What Does Glucagon Receptor Agonism Add to the Effects of GIP and GLP-1 Receptor Agonism? -...
https://pubmed.ncbi.nlm.nih.gov/36313764/
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of...
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes (T2D). The...